CTRG B09/00 A phase I/II study of weekly paclitaxel, UFT, and leucovorin in patients with metastatic breast cancer

Phase 1

Active, not recruiting

• Conditions: Metastatic breast cancer; Cancer - Breast

• Registration Number: ACTRN12605000464662
• Lead Sponsor: CTRG initiated study

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2005-09-23
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: Female
• Target Recruitment: 60

Inclusion Criteria

First line metastatic, female, adequate haematological, renal and hepatic function.

Exclusion Criteria

No exclusion criteria

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To define the maximum tolerated dose of the combination in a new schedule[];To define the toxicity profiles of the combination in a new schedule[]

Secondary Outcome Measures

Name	Time	Method
Response rate[];Response duration[];Time to treatment failure[]